Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions

Beitelshees, A. L.; Horenstein, R. B.; Vesely, M. R.; Mehra, M. R.; Shuldiner, A. R.
March 2011
Clinical Pharmacology & Therapeutics;Mar2011, Vol. 89 Issue 3, p455
Academic Journal
The article focuses on the association between cytochrome P450 2C19 (CYP2C19) and clopidogrel response in patients under percutaneous coronary interventions. It says that studies from 2008 show that CYP2C19*2 genotype increase the risk of patients to have cardiovascular events but the Platelet Inhibition and Patient Outcomes (PLATO) data reveal no relationship between outcomes and the ABCB1 genotype. It adds that physicians could continue using clopidogrel or use other antiplatelet agents.


Related Articles

  • Drug and Medical Device Interactions: Stent Thrombosis and Personalizing Clopidogrel Therapy. Giusti, Betti; Gori, Anna Maria; Marcucci, Rossella; Saracini, Claudia; Vestrini, Anna; Abbate, Rosanna // Current Pharmacogenomics & Personalized Medicine;2010, Vol. 8 Issue 2, p124 

    Antiplatelet therapy with aspirin and clopidogrel, aimed to inhibit platelet function and reactivity, is the recommended standard of care for reducing the occurrence of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stent...

  • The role of genetic factors in clopidogrel antiplatelet therapy. Cieślewicz, Artur Robert; Kaźmierczak, Ewa; Jabłecka, Anna // Advances in Interventional Cardiology;2012, Vol. 8 Issue 2, p126 

    Thienopyridine derivative antiplatelet agents play an important role in the treatment of coronary artery disease. Clopidogrel is a drug blocking action of the platelet ADP receptor (P2Y12). It is applied in the form of a prodrug that requires metabolic activation by cytochrome P450 enzymes. The...

  • Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease. Terpening, Chris // Clinical Medicine Insights: Cardiology;2010, Issue 4, p117 

    The thienopyridine antiplatelet agent clopidogrel is an effective drug for the prevention of vascular events. However, data has accumulated over time to suggest it is prone to significant interpatient variability. While there are several factors that contribute to this, one of the most important...

  • Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations. Karathanos, Athanasios; Geisler, Tobias // Molecular Diagnosis & Therapy;Jun2013, Vol. 17 Issue 3, p123 

    Antiplatelet therapy is the cornerstone of the treatment for patients with coronary artery disease (CAD). Dual therapy with clopidogrel and aspirin is currently the standard treatment after percutaneous coronary interventions. However, despite the use of clopidogrel, a considerable number of...

  • Triple versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Adding Cilostazol to Aspirin and Clopidogrel? Niazi, asfandyar K.; DiNicolantonio, James J.; Lavie, Carl J.; O'Keefe, James H.; Meier, Pascal; Bangalore, Sripal // Cardiology;Nov2013, Vol. 126 Issue 4, p233 

    Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes. Additionally, novel P2Y12 receptor antagonists such as prasugrel and ticagrelor are even recommended over clopidogrel in certain clinical guidelines. Despite the...

  • The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. Neergaard-Petersen, Søs; Hvas, Anne-Mette; Grove, Erik Lerkevang; Larsen, Sanne Bøjet; Gregersen, Søren; Kristensen, Steen Dalby // PLoS ONE;7/6/2015, Vol. 10 Issue 7, p1 

    Background: Hyperglycaemia may attenuate the antiplatelet effect of aspirin and thereby increase the risk of cardiovascular events. We investigated the influence of increased haemoglobin A1c (HbA1c) levels on platelet aggregation and turnover in a large cohort of patients with coronary artery...

  • SHORT CUTS. Fister, Kristina // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p536 

    This section discusses various health-related studies published in different journals. A study published in the "New England Journal of Medicine" estimated the cumulative doses of radiation received by patients in the U.S. during imaging procedures. Another study published in the same journal...

  • Progress of Antiplatelet Pharmacogenomics. Oestreich, Julie H. // Current Drug Targets;Nov2011, Vol. 12 Issue 12, p1848 

    Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies...

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics